Cenvacibart clinical trials
Also written REGN7508.
How each study uses cenvacibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the cenvacibart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2026 (8)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 0
Often tested with
Tested in the same studies.
Amrecibart (6) · REGN9533 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5, 2 in phase 3
Studies that test cenvacibart, phase 3 first.
- Feb 2027REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in AdultsPhase 3 · Regeneron Pharmaceuticals
- May 2027REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult ParticipantsPhase 3 · Regeneron Pharmaceuticals
- Feb 2027Safety in Adult Participants With Atrial Fibrillation Who Are Treated With AnticoagulationPhase 2 · Regeneron Pharmaceuticals
- Mar 2027Healthy Adult Participants Trial Comparing Different Cenvacibart PresentationsPhase 1 · Regeneron Pharmaceuticals
- Apr 2027Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on HemodialysisPhase 1 · Regeneron Pharmaceuticals
Studies
Open first, then newest update. How each study uses cenvacibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is UnsuitableRecruitingPhase 3Regeneron PharmaceuticalsNCT07430956Written as REGN7508
- REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in AdultsRecruitingPhase 3Regeneron PharmaceuticalsNCT07015905Written as REGN7508
- Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic CancersRecruitingPhase 3Regeneron PharmaceuticalsNCT07493304Written as REGN7508
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial FibrillationRecruitingPhase 3Regeneron PharmaceuticalsNCT07626411Written as REGN7508
- Safety in Adult Participants With Atrial Fibrillation Who Are Treated With AnticoagulationRecruitingPhase 2Regeneron PharmaceuticalsNCT07175428Written as REGN7508
- REGN7508 in Adult Participants for Prevention of Cancer-Associated ThrombosisRecruitingPhase 3Regeneron PharmaceuticalsNCT07410117Written as REGN7508
- REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult ParticipantsRecruitingPhase 3Regeneron PharmaceuticalsNCT07213778Written as REGN7508
- Healthy Adult Participants Trial Comparing Different Cenvacibart PresentationsNot yet recruitingPhase 1Regeneron PharmaceuticalsNCT07876505Written as Cenvacibart
- A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult ParticipantsNot yet recruitingPhase 3Regeneron PharmaceuticalsNCT07876492Written as Cenvacibart
- Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on HemodialysisRecruitingPhase 1Regeneron PharmaceuticalsNCT07759167Written as REGN7508
- Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)RecruitingPhase 3Regeneron PharmaceuticalsNCT07697599Written as REGN7508
- A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult ParticipantsCompletedPhase 2Regeneron PharmaceuticalsNCT06454630Written as REGN7508
- A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)CompletedPhase 2Regeneron PharmaceuticalsNCT06299111Written as REGN7508
- Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult ParticipantsCompletedPhase 1Regeneron PharmaceuticalsNCT06444178Written as REGN7508
- A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult ParticipantsCompletedPhase 1Regeneron PharmaceuticalsNCT05603195Written as REGN7508 (IV)
Given beside what is tested · 1 — cenvacibart is usual care or a partner of the new treatment
Codes
What other systems call cenvacibart · ClinicalTrials.gg INT015301
- UNII (FDA) 6NM5PD4YTHCENVACIBARTOne source FDA
- NCI Thesaurus C214498CenvacibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6NM5PD4YTH | CENVACIBART | One source FDA |
| NCI Thesaurus | C214498 | Cenvacibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.